AbbVie Inc. (ABBV) |
|
86.98 0.26 (0.3%)
|
12-06 16:02 |
|
Open: |
87.21 |
Pre. Close: |
86.72 |
|
High:
|
87.71 |
Low:
|
86.78 |
|
Volume:
|
6,045,168 |
Market Cap:
|
128628M |
|
|
|
|
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
87.786 - 88.405 |
88.405 - 88.885 |
|
Low:
|
85.608 - 86.273 |
86.273 - 86.789 |
|
Close:
|
86.125 - 87.139 |
87.139 - 87.925 |
|
Technical analysis |
as of: 2019-12-06 4:32:15 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 105.60 One year: 123.34 |
| Support: |
Support1: 83.44 Support2: 79.13 |
| Resistance: |
Resistance1: 90.41 Resistance2: 105.60 |
| Pivot: |
87.44  |
| Moving Average: |
MA(5): 86.78 MA(20): 87.16
MA(100): 74.23 MA(250): 77.77 |
| MACD: |
MACD(12,26): 1.72 Signal(9): 2.25 |
| Stochastic oscillator: |
%K(14,3): 32.48 %D(3): 30.27 |
| RSI: |
RSI(14): 59.90 |
| 52-week: |
High: 92.99 Low: 62.66 Change(%): -0.7 |
| Average Vol(K): |
3-Month: 759472 10-Days: 662505 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.ABBV has closed above bottom band by 37.5%. Bollinger Bands are 44.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to ABBV's normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
2019-12-06
Worldwide Chronic Disease Management Industry Insights, 2018-2024: Emphasis on Advance Needle-Free Drug Delivery Technologies, Diagnostic Methods, and Smart Device Technologies
DUBLIN , Dec. 6, 2019 /PRNewswire/ -- The "Chronic Disease Management: Therapeutics, Device Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for chronic disease management through various therapeutics and advanced device technologies. Report Scope Brief outline of the global markets and therapeutic device technologies for chronic disease management Analyses of global market trends with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Key insight into the current state of chronic diseases and disorders, with an emphasis on advance needle-free drug delivery technologies, diagnostic methods, and smart device technologies that support effective disease state management Data corresponding to global chronic disease management markets by disease type that includes various chronic diseases, therapeutic drugs, treatment adherence devices & systems, drug delivery technologies, and treatment & management providers Regulatory structure for pharmaceuticals and medical devices, pricing and reimbursement structure, marketed and pipeline products, and major developments influencing the market Detailed company profiles and competitive landscape of major market players, including Roche, AbbVie, Johnson & Johnson, Bristol-Myers Squibb, Merck and GlaxoSmithKline Market Insights This market growth is fueled by a growing geriatric population, changing lifestyle, increasing prevalence of chronic diseases, superior clinical results of new drugs and biologics, increasing trend of digital health, the U.S.
2019-12-04
Allergan : Form 8.3 - Abbvie Inc | MarketScreener
TIDM0QCV TIDM0Y7T FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN… | December 4, 2019
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: New York Stock Exchange |
| Sector: Healthcare |
| Industry: Drug Manufacturers - Major |
| Shares Out. (M) |
1480.00 |
| Shares Float (M) |
1480.00 |
|
% Held by Insiders
|
0.09 |
|
% Held by Institutions
|
71.89 |
|
Shares Short (K)
|
60800 |
|
Shares Short P. Month (K)
|
|
Stock Financials |
|
EPS
|
2.180 |
|
Book Value (p.s.)
|
-5.560 |
|
PEG Ratio
|
2.88 |
|
Profit Margin
|
9.90 |
|
Operating Margin
|
41.11 |
|
Return on Assets (ttm)
|
13.4 |
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
3.0 |
|
Gross Profit (p.s.)
|
16.919 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
10.446 |
|
Qtrly Earnings Growth
|
-31.40 |
|
Operating Cash Flow (M)
|
13440.00 |
|
Levered Free Cash Flow (M)
|
10290.00 |
Stock Valuations |
|
P/E
|
39.90 |
|
P/E Growth Ratio
|
|
|
P/BV
|
-15.64 |
|
P/S
|
3.92 |
|
P/CF
|
9.58 |
Dividends & Splits |
|
Dividend
|
4.280 |
|
Dividend Yield
|
0.05 |
|
Dividend Pay Date
|
2020-02-14 |
|
Ex-Dividend Date
|
2020-01-14 |
|
Forward Dividend
|
4.720 |
|
Last Split Date
|
|
|
Last Split Ratio
|
-1e+010 |
|
7 Binary Options
|
|
Your Ad Here
|
|
